Stereotaxis 3Q 2026: Revenue $8.93M, EPS ($0.07) — 10-Q Summary

Stereotaxis reported 3Q 2026 revenue of $8.93M, up 20% YoY, driven by higher system sales. Net loss was $6.8M, slightly wider than the prior year. Gross margin fell to 44% from 55% due to product mix. Robocath acquisition contributed minimal revenue and a $1.6M net loss.

Original reporting
Published Nov 16, 2026, 5:51 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 5:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Stereotaxis 3Q 2026: Revenue $8.93M, EPS ($0.07) — 10-Q Summary — source image
Decision brief

The 30-second read

$STXSBearishMed
01

Why it matters

Investors will likely focus on whether system sales growth can offset gross margin compression and whether Robocath’s early post-acquisition losses are temporary versus indicative of longer-term cost structure.

02

Market read

A fresh quarterly print with explicit margin and acquisition-integration details can shift expectations for near-term profitability and acquisition value.

03

What to watch

Gross margin decline is attributed to product mix; traders may want to separate mix effects from structural margin deterioration and watch whether disposables growth offsets system margin pressure.

Relevance 6/10Novelty 6/10Timing: after-hours/filing day, based on the Nov. 16, 2026 10-Q summary

Background

The piece is a short 10-Q summary for Stereotaxis’ 3Q 2026, including segment revenue drivers and the July 7 Robocath acquisition’s early contribution.

Company-level read

Ticker impact

$STXSBearishMedium confidence
Context

Stereotaxis reports 3Q 2026 revenue of $8.93M and diluted EPS of ($0.07), with gross margin falling to 44% and Robocath losses post-close.

Expected impact

Likely downside bias as investors weigh higher system sales against lower gross margin and Robocath’s $1.6M net loss contribution.

Evidence & confidence

The article provides fresh quarterly datapoints (revenue, EPS, gross margin, and Robocath post-close contribution) that directly affect earnings power and acquisition integration expectations.

Market effects

Highlights margin sensitivity in medical device systems and the integration cost profile of acquired robotics/disposables businesses.

No clear regional spillover indicated beyond US-listed small-cap medtech sentiment.

Limited global relevance; story is company-specific with acquisition integration details.

Counterpoint

Revenue growth driven by systems could still indicate improving demand, and the Robocath post-close revenue is minimal, so losses may normalize as integration progresses.

Key entities

  • Stereotaxis, Inc.

    US-listed medical device company reporting 3Q 2026 revenue, EPS, gross margin, and early Robocath acquisition contribution.

  • Robocath

    Acquisition closed July 7; contributed less than $0.1M revenue and a $1.6M net loss post-acquisition per the summary.

Related articles

$STXSHigh

Why is Stereotaxis stock sliding today?

Stereotaxis (STXS) fell 14.6% after Q3 2026 results missed estimates, with a $0.07 adjusted loss per share and $8.9M revenue. Supply shortages of MAGiC catheters and a $24M convertible note financing at $1.21/share raised concerns. TD Cowen cut its price target to $2.00. The stock hit a 52-week low of $0.80.

$STXSMedAI 8/10

20 robotic heart procedures had no device-related adverse events.

Stereotaxis (NYSE: STXS) announced 100% clinical success and no device-related adverse events in 20 first-in-human robotic heart procedures using Robocath's next-generation system. The study, presented at TCT 2026, showed 95% technical success and no physician radiation exposure. Robocath is a subsidiary of Stereotaxis, focusing on advanced robotic innovations for interventional cardiology.

$STXSMedAI 8/10

Stereotaxis (STXS) Q2 2026 Earnings Call Transcript

Stereotaxis (STXS) reported Q2 2026 revenue of $7.7M, down from $8.8M YoY due to no robotic system delivery. Robotic catheter revenue grew 270% sequentially to $1M. Recurring revenue increased to $6.2M. Gross margin was 58%. The company expects cash flow profitability by H1 2027 and guided Q3/Q4 recurring revenue at $7M and $8M, respectively. Management highlighted supply constraints and transition risks.

$STXSMed

Stereotaxis Reports 2026 Second Quarter Financial Results & Business Updates

Stereotaxis, Inc. (STXS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Stereotaxis Reports 2026 Second Quarter Financial Results & Business Updates ● Robotic catheter revenue surpasses $1M in the quarter, growing 270% sequentially ● First GenesisX robotic system purchase by US hospital to be installed this fall ● Multiple Synchrony digi

$NIUMed

Niu Tech (NIU) Q3 2026 Earnings Call Transcript

Niu Tech (NIU) reported Q3 2026 earnings, with total sales volume up 15.4% YoY to 534,057 units. Revenue was RMB 1.71 billion, up 1.2% YoY. China sales grew 8.6% YoY, while international sales surged 226%. Gross margin expanded to 18.0%. The company highlighted strong growth in electric motorcycles, which accounted for 56% of China sales, and strategic product launches.